clock is ticking, page-7

Hi Surges,

GSK recently completed a 5 year clinical trial for what they have simply labelled as "SB-705498" - a novel "TRPV1 receptor antagonist".

Further research confirms that this study is indeed relating to a new analgesic discovery belonging to the triptan family.

"Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose. SB 705498 is a novel, first in class TRPV1 receptor antagonist under development for the treatment of migraine pain.

Preclinical experiments have demonstrated that the TRPV1 receptor is expressed both centrally and peripherally in the trigeminal system and inhibition of TRPV1 with SB 705498 can both prevent and reverse established central sensitisation".

GSK have put it through a number of clinical trials for pain management including the following.

Clinical Trials - GSK - SB-705498 Dental Pain Study After Tooth Extraction

I'm very interested to see todays announcement. I can't remember PNO ever requesting a trading halt for a Capital Raising?

I think the market might be in for a big surprise from our little sister very soon ;)